Chillo Serawit Lakew, Woldesemayat Endrias Markos, Dangisso Mesay Hailu
College of Medicine and Health Sciences, School of Public Health, Hawassa University, Hawassa, Ethiopia.
Ethiopian Public Health Institute, Addis Ababa, Ethiopia.
Reprod Health. 2025 Jan 8;22(1):2. doi: 10.1186/s12978-024-01917-8.
Trials were inconsistent while reporting findings on the benefits of the intermittent regimen. Recent conclusive evidence to show overall effect was limited. This review compared intermittent and daily iron folic acid supplementation (IFAS) on pregnancy outcomes. Protocol is registered at Prospero with registration number CRD42023409161. The major data sources searched were PubMed/Medline, Hinari, and Google Scholar. The process was reported using a PRISMA flow diagram. The included studies were trials with English language reports. The population was pregnant women. The intervention was an intermittent oral iron folic acid regimen, and the control was a daily regimen. The outcome measures were blood hemoglobin level, side effects, and medication adherence. The GRADE approach and Cochrane collaboration tool were used in the quality evaluation. The selected trials were narrated for basic characteristics and major findings. The standardized mean difference was used for continuous outcomes and the relative risk for binary outcomes. A sensitivity analysis was performed to report the robustness of the estimate. Twenty-two trials were selected for analysis. The quality of the evidence ranges from high to very low. Maternal blood hemoglobin levels were different between the intermittent and daily groups (mean difference (MD), - 0.24 g/dl; 95%CI, - 0.35, - 0.12). However, either early initiation or frequently intermittent regimen in the subgroup analysis showed no difference in hemoglobin levels. Intermittent regimens had lower gastric side effects (relative risk (RR), 0.27; 95%CI, 0.11, 0.69) and better medication adherences (relative risk (RR), 1.6; 95%CI, 1.34, 1.91). There was no clear evidence of a difference in anaemia incidence between the groups (relative risk (RR), 1.09; 95%CI, 0.77, 1.54). The overall level of hemoglobin in pregnancy was different between the groups. However, anaemia incidence was similar. The combined results suggest the intermittent regimen had better benefits in pregnancy than daily.
在报告间歇性治疗方案的益处方面,各试验结果并不一致。近期显示总体效果的确凿证据有限。本综述比较了间歇性和每日补充铁叶酸(IFAS)对妊娠结局的影响。方案已在国际前瞻性系统评价注册库(Prospero)注册,注册号为CRD42023409161。检索的主要数据源为PubMed/Medline、Hinari和谷歌学术。使用PRISMA流程图报告检索过程。纳入的研究为英文报告的试验。研究对象为孕妇。干预措施为间歇性口服铁叶酸方案,对照为每日方案。结局指标为血红蛋白水平、副作用和药物依从性。采用GRADE方法和Cochrane协作工具进行质量评估。对所选试验叙述了基本特征和主要发现。连续型结局采用标准化均数差,二分类结局采用相对危险度。进行敏感性分析以报告估计值的稳健性。选择了22项试验进行分析。证据质量从高到极低不等。间歇性组和每日组孕妇的血红蛋白水平存在差异(均数差(MD),-0.24 g/dl;95%置信区间,-0.35,-0.12)。然而,亚组分析中早期开始或频繁间歇性方案在血红蛋白水平上均无差异。间歇性方案的胃部副作用较低(相对危险度(RR),0.27;95%置信区间,0.11,0.69),药物依从性较好(相对危险度(RR),1.6;95%置信区间,1.34,1.91)。两组之间贫血发生率无明显差异(相对危险度(RR),1.09;95%置信区间,0.77,1.54)。两组之间孕期血红蛋白总体水平存在差异。然而,贫血发生率相似。综合结果表明,间歇性方案在孕期比每日方案有更好的益处。